Please login to the form below

kinase inhibitor

This page shows the latest kinase inhibitor news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s Rinvoq recommended by NICE for Crohn's disease

The authorisation, which makes Rinvoq the first oral Janus Kinase (JAK) inhibitor available for this indication in England and Wales, specifically applies to patients who have had an inadequate response, lost

Latest news

Bristol Myers Squibb’s Sotyktu approved by MHRA for plaque psoriasis

The European Commission’s decision, which followed a recommendation from the Committee for Medicinal Products for Human Use earlier this year, made Sotyktu the first oral, selective, allosteric tyrosine kinase 2 ... inhibitor in the EU for the
Amgen and TScan Therapeutics partner to identify new Crohn’s disease targets

The partnership comes less than a month after AbbVie's Rinvoq (upadacitinib) was approved by the European Commission as the first oral Janus Kinase inhibitor to treat adults with moderately to
Sobi to acquire CTI BioPharma for approximately $1.7bn

The deal will grant Sobi access to the US biopharma’s recently-approved Vonjo (pacritinib), a novel oral kinase inhibitor for patients with myelofibrosis and severe thrombocytopenia.
AbbVie’s Rinvoq approved by EC for Crohn's disease

The therapy is now the first oral JAK inhibitor authorised to treat this patient population. ... AbbVie’s Rinvoq (upadacitinib) has been approved by the European Commission (EC) as the first oral Janus Kinase (JAK) inhibitor to treat adults with
Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis

The approval, which follows a recommendation from the Committee for Medicinal Products for Human Use earlier this year, makes Sotyktu the first oral, selective, allosteric tyrosine kinase 2 inhibitor in the

More from news
Approximately 0 fully matching, plus 227 partially matching documents found.

Latest Intelligence

AI: the smart money is on the smart thinking

Using machine learning, a small team of four researchers were able to identify an initial 370 kinase inhibitors, and then quickly narrow this down to the six most likely to work – ... Using GENTRL, the company was able to design a novel DDR1 kinase
Can protein degraders unlock ‘undruggable’ drug targets?

Some groups are focusing on SNIPERs – an acronym for Specific and Non-genetic Inhibitor of apoptosis protein-dependent Protein Erasers. – ... These compounds could be used to tackle resistance to kinase inhibitor drugs, for example.
Deal Watch January 2018

Acquisition company - remaining 90%. 9, 000. Impact Biomedicines/ Celgene. Fedratinib, highly selective JAK2 kinase inhibitor for myelofibrosis (p3) and polycythemia vera. ... This acquisition brings tucatinib, an oral tyrosine kinase inhibitor that is
Deal Watch September 2016

No financial terms were disclosed. Genentech signed an exclusive licence [global excluding South Korea] with Hanmi Pharmaceutical to develop and market HM95573, a pan-RAF inhibitor. ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective
Deal Watch June 2016

acquisition assets. 350. CrystalGenomics/ Aptose Biosciences. CG026806 inhibitor of Bruton's tyrosine kinase, FMS-like tyrosine kinase 3 and Aurora kinases (preclinical). † ... acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe.

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

AZ appoints Susan Galbraith as executive vice president, oncology R&D

This includes PARP inhibitor Lynparza (olaparib), third-generation tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib), the recently approved MET inhibitor Orpathys (savolitinib) and Koselugo (selumetinib) – indicated for the treatment of
Akinion appoints Dr Richard Jones as CEO

In his new role at Akinion Pharmaceuticals Dr Jones will oversee a company focused on acute myeloid leukaemia and its lead candidate drug AKN-028, a small molecule kinase inhibitor currently
Creabilis names Catherine Moukheibir as chairman of the board

Moukheiber will head the board as it progresses its lead product CT327, a first-in-class selective TrkA kinase inhibitor for the treatment of pruritus (itching) due to psoriasis.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Account Manager, Healthcare Marketing Creative Agency, Fixed ter...: Highly competitive salary

Account Manager, 6 month contract, Healthcare Brand communicatio...: Highly competitive salary

Market Access Director, six figure base salary and £5K joining b...: Highly competitive salary

Account Director, Healthcare Marketing Creative Agency, Fixed te...: Highly competitive salary

Home Based Account Manager, Medical Communications, UK, Pharma/M...: Highly competitive salary

Senior Medical Copywriter - Highly Awarded Advertising Agency: £50,000 - £60,000 yearly

AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer

PMHub

Add my company

Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

Patient Clinical Trial & Communications Plan Review: A Customer Story: ...
Working together to achieve better patient pathways: Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
Design-thinking. Iterating for continuous improvement.: How design can lead improvement within Pharma...

Email:
Password:

Please login to the form below

kinase inhibitor

Subscribe to our email news alerts

Quick links